Concord fermentation Kirin long-lasting EPO "Dayipotin alpha injection" approved in China

On June 19, Concord Fermentation Kirin daipotin alpha injections were approved for the treatment of anemia in patients with chronic renal failure hemodialysiserythropoietin (EPO) is a class of classic anemia treatment drugs, according to the feeding cycle is divided into a generation of short-acting products and second-generation long-acting productsThe international EPO market is dominated by Daipotin alpha, a drug developed jointly by Amin/Concord Fermented Kirin and approved by the FDA for listing in September 2001Aranesp's peak sales in 2006 were $4.12 billionSince then, Sales of Aranesp have declined, to $1,729 million in 2019, due to FDA restrictions on the use of EPO productsdomestic EPO products currently listed mainly for a generation of short-acting products, of which Sansheng Pharmaceutical's restructuring of erythropoietin products Ibio and Sebor 2019 market share of 41.6 percentDomestic currently there is no domestic long-acting EPO preparation approved, Sansheng Pharmaceutical's second-generation recombinant recombinant products NuPIAO and polyglycol long-acting erythropoietin RD001 is currently in the clinical stage.